Shanghai Fosun Pharmaceutical(600196.SH)'s holding subsidiary Fosun Pharma Alliance has received the acceptance of drug registration application.
Fosun Pharma (600196.SH) released an announcement stating that its holding subsidiary Fosun Wanbang (Jiangsu) Pharmaceutical Group Co.,Ltd...
Shanghai Fosun Pharmaceutical (600196.SH) announced that its controlling subsidiary Fosun Pharma has recently had its drug registration application for the compound drug Ripretinib (project code: SAF-189, registration classification: chemical drug class 1; hereinafter referred to as "the new drug") accepted by the National Medical Products Administration.
This new drug is an innovative small molecule chemical drug intended for the treatment of non-small cell lung cancer (ALK+) and non-small cell lung cancer (ROS1+). The indication for this application is for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK) positivity.
Related Articles

Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.

US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.

Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.

US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.

Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


